Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma

详细信息    查看全文

• 作者：Tracey A. Bradshaw ; Simon P. Matusiewicz ; Graham K. Crompton ; J. Alastair Innes ; Andrew P. Greening
• 关键词：Acute asthma ; Exacerbation ; Magnesium sulphate
• 刊名：Respiratory Medicine
• 出版年：2008
• 出版时间：January 2008
• 年：2008
• 卷：102
• 期：1
• 页码：143-149
• 全文大小：207 K

文摘

Summary

Background

Treatment of acute asthma is based on rapid reversal of bronchospasm and airway inflammation. Magnesium sulphate (MgSO₄) is known to have a bronchodilator effect on smooth muscle but studies have shown conflicting results on its efficacy in acute asthma, although its use is recommended in national and international guidelines.

Aims

<p>To determine if intravenous MgSO₄, when used as an adjunct to standard therapy, improves the outcome in acute asthma.

Methods

<p>A double blind, randomised placebo controlled trial comparing 1.2 g MgSO₄ with standard therapy in adult patients with acute asthma. Patients had a PEF 75 % predicted and all were treated with oxygen, nebulised salbutamol and ipratropium, and IV hydrocortisone. They then received 1.2 g IV MgSO₄ or placebo. Outcome measures were % predicted PEF at 60 min and hospital admission rates.

Results

<p>One hundred and twenty nine patients were studied. Placebo and active treatment groups were well matched at baseline. MgSO₄ had no benefit with regards hospital admission rates or % predicted PEF at 60 min (p=0.48) for the whole group, or for subgroups of life-threatening (p=0.85), severe (p=0.63) and moderate (p=0.67) acute asthma.

Conclusion

<p>This study did not show additional benefit from 1.2 g IV MgSO₄ when given as an adjunct to standard therapy for acute asthma.